These two studies hypothesize that inhibiting HDAC6 sustains the tumor suppressor activity of p53 and PTEN proteins and therefore, HDAC6i could benefit as antitumor agents only in tumors expressing p53 and PTEN. Here, TP53 is linked to neoplasm.